Lazard Asset Management
IONS icon

Lazard Asset Management’s Ionis Pharmaceuticals IONS Stock Holding History

Lazard Asset Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5M Buy
132,480
+107,070
+421% +$8.06M 0.02% 444
2026
Q1 		$1.91M Sell
25,410
-20,992
-45% -$1.66M ﹤0.01% 910
2025
Q4 		$3.67M Sell
46,402
-17,389
-27% -$1.31M 0.01% 653
2025
Q3 		$4.17M Buy
63,791
+3,042
+5% +$149K 0.01% 630
2025
Q2 		$2.4M Sell
60,749
-9
-0% -$295 ﹤0.01% 953
2025
Q1 		$1.83M Buy
60,758
+54,201
+827% +$1.77M ﹤0.01% 998
2024
Q4 		$228K Sell
6,557
-16,366
-71% -$612K ﹤0.01% 1568
2024
Q3 		$917K Buy
22,923
+13,408
+141% +$624K ﹤0.01% 1111
2024
Q2 		$452K Buy
9,515
+1,660
+21% +$68.1K ﹤0.01% 1235
2024
Q1 		$339K Buy
7,855
+1,214
+18% +$57.9K ﹤0.01% 1147
2023
Q4 		$335K Buy
6,641
+84
+1% +$4.02K ﹤0.01% 1228
2023
Q3 		$296K Buy
6,557
+1,420
+28% +$58.6K ﹤0.01% 1271
2023
Q2 		$209K Sell
5,137
-1,051
-17% -$40.4K ﹤0.01% 1331
2023
Q1 		$220K Buy
6,188
+2,465
+66% +$92.6K ﹤0.01% 1283
2022
Q4 		$139K Sell
3,723
-322
-8% -$13.5K ﹤0.01% 1398
2022
Q3 		$178K Sell
4,045
-1,580
-28% -$66.6K ﹤0.01% 1294
2022
Q2 		$207K Buy
5,625
+568
+11% +$21.4K ﹤0.01% 1275
2022
Q1 		$186K Sell
5,057
-757
-13% -$24.8K ﹤0.01% 1269
2021
Q4 		$176K Buy
5,814
+4,554
+361% +$143K ﹤0.01% 1306
2021
Q3 		$42K Sell
1,260
-631
-33% -$23.8K ﹤0.01% 1767
2021
Q2 		$74K Buy
1,891
+1,854
+5,011% +$72.6K ﹤0.01% 1436
2021
Q1 		$1K Sell
37
-2,009
-98% -$112K ﹤0.01% 1825
2020
Q4 		$115K Buy
2,046
+872
+74% +$43.5K ﹤0.01% 1163
2020
Q3 		$55K Sell
1,174
-441
-27% -$24.5K ﹤0.01% 1158
2020
Q2 		$95K Sell
1,615
-1,024
-39% -$57K ﹤0.01% 1027
2020
Q1 		$124K Sell
2,639
-9,931
-79% -$554K ﹤0.01% 967
2019
Q4 		$759K Buy
+12,570
New +$749K ﹤0.01% 777
2016
Q4 		– Sell
-50,000
Closed -$1.83M – 1017
2016
Q3 		$1.83M Buy
+50,000
New +$1.56M ﹤0.01% 628

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Lazard Asset Management's IONS Position: Q2 2026 in Review

Lazard Asset Management increased its Ionis Pharmaceuticals (IONS) stake by 421% in Q2 2026, buying an estimated $8.06M and bringing the position to 132,480 shares worth $10.5M. The position accounts for 0.02% of the portfolio, ranked #444.

Lazard Asset Management first reported a position in IONS in Q3 2016 and has held it in 28 quarters since. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • Lazard Asset Management held 132,480 shares of Ionis Pharmaceuticals worth $10.5M as of Q2 2026.
  • Lazard Asset Management bought 107,070 Ionis Pharmaceuticals shares in Q2 2026, an estimated $8.06M.
  • Ionis Pharmaceuticals made up 0.02% of Lazard Asset Management's portfolio in Q2 2026, its #444 holding.
  • Lazard Asset Management first reported a position in Ionis Pharmaceuticals in Q3 2016 and has held it in 28 quarters since.
  • 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on Lazard Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.